NovaBridge Biosciences (NBP) CMO reports options, RSUs and shares on Form 3
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
NovaBridge Biosciences Chief Medical Officer Dennis Phillip Andrew filed an initial ownership report, listing his equity awards and share holdings. He holds 2024 employee share options over 494,510 underlying Ordinary Shares at an exercise price of 1.8200 and additional options over 186,300 underlying Ordinary Shares at 1.0500, both expiring in 2034. He also holds 92,724 restricted share units tied to Ordinary Shares and 142,740 Ordinary Shares directly. The footnotes explain that the securities may be represented by ADSs and that the options and RSUs vest over four years under specified schedules.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Dennis Phillip Andrew
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | 2024 Employee Share Option (right to buy) | -- | -- | -- |
| holding | 2024 Employee Share Option (right to buy) | -- | -- | -- |
| holding | Restricted Share Units | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
2024 Employee Share Option (right to buy) — 494,510 shares (Direct);
Restricted Share Units — 92,724 shares (Direct);
Ordinary Shares — 142,740 shares (Direct)
Footnotes (1)
- The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. Reported securities are represented by 62,061 ADSs. Number of underlying securities and exercise price expressed in terms of ADSs. The option was granted on June 17, 2024. The option vests and become exercisable over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 17th day of each third month. The option was granted on September 3, 2024 and is fully vested and exercisable. On June 17, 2024, the Reporting Person was granted 164,840 restricted share units ("RSUs"). Each RSU represents a contingent right to receive one ADS. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 17th day of each third month.
FAQ
What does NovaBridge Biosciences (NBP) Chief Medical Officer report on this Form 3?
The filing lists Dennis Phillip Andrew’s existing equity position, including options, restricted share units, and Ordinary Shares. It is an initial ownership statement, not a record of new buying or selling activity in NovaBridge Biosciences securities.
How many options does the NovaBridge Biosciences (NBP) CMO hold according to the Form 3?
He holds 2024 employee share options over 494,510 underlying Ordinary Shares at an exercise price of 1.8200 and additional options over 186,300 underlying Ordinary Shares at 1.0500, both expiring in 2034, as disclosed in the derivative holdings summary.
Are NovaBridge Biosciences (NBP) securities in this Form 3 represented by ADSs?
Footnotes note that the Ordinary Shares may be represented by American Depositary Shares, where each 10 ADSs represent 23 Ordinary Shares, and that the reported securities are represented by 62,061 ADSs, with option terms expressed in ADS-equivalent terms.
Does this NovaBridge Biosciences (NBP) Form 3 show any insider buying or selling?
No buy or sell transactions are indicated. All entries are classified as holdings with unknown transaction codes, and the transaction summary shows zero buys, zero sells, and only holding entries, consistent with an initial ownership report for a new reporting insider.
NovaBridge Biosciences